
Life Science companies should bear in mind that there are other emerging markets than the BRIC countries and make sure they are locally present, if they want to succeed, says the professional services firm Deloitte.
The conclusion appears in a recently published survey of growth strategies from the firm focusing on the Next11 countries, which are Egypt, Pakistan, Indonesia, Iran Turkey, Vietnam, the Philippines, Nigeria, Bangladesh, Mexico and South Korea.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app